Cardiol Therapeutics (NASDAQ:CRDL – Free Report) had its target price increased by Canaccord Genuity Group from $6.00 to $8.00 in a report published on Thursday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $9.00 target price on shares of Cardiol […]